Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Raltegravir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNE1 | P15382 | 1/20 | 0.97 |
| ▸ | CCR1 | P32246 | 1/20 | 0.97 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.97 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | SCD | O00767 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Raltegravir SCHEMBL51817 | 0.98 | KCNE1 (1.00) | KCNE1CCR1KCNQ1MEN1KMT2A | |
| Raltegravir SCHEMBL2562078 | 0.97 | KCNE1 (0.98) | KCNE1CCR1KCNQ1MEN1KMT2A | |
| Raltegravir SCHEMBL2565413 | 0.97 | KCNE1 (0.98) | KCNE1CCR1KCNQ1MEN1KMT2A | |
| Raltegravir SCHEMBL1191960 | 0.97 | KCNE1 (0.98) | KCNE1CCR1KCNQ1MEN1KMT2A | |
| Raltegravir SCHEMBL29420846 | 0.97 | KCNE1 (0.98) | KCNE1CCR1KCNQ1MEN1KMT2A | |
| Raltegravir SCHEMBL2555854 | 0.97 | KCNE1 (0.98) | KCNE1CCR1KCNQ1MEN1KMT2A | |
| Raltegravir SCHEMBL2562938 | 0.94 | KCNE1 (0.92) | KCNE1CCR1KCNQ1MEN1KMT2A | |
| Raltegravir SCHEMBL2548211 | 0.94 | KCNE1 (0.91) | KCNE1CCR1KCNQ1MEN1KMT2A | |
| Raltegravir SCHEMBL31690801 | 0.93 | KCNE1 (0.90) | KCNE1CCR1KCNQ1MEN1KMT2A | |
| SCHEMBL13135874 | 0.91 | KCNE1 (0.87) | KCNE1CCR1KCNQ1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2796458-A1 | Crystalline raltegravir sodium salts | Teva Pharmaceutical Industries Ltd. (IL) | 2014-10-29 | — | — | EP | disclosed |
| EP-2545048-B1 | RALTEGRAVIR SALTS AND CRYSTALLINE FORMS THEREOF | TEVA PHARMA (IL) | 2014-10-08 | — | — | EP | disclosed |
| US-20140256755-A1 | Raltegravir Salts And Crystalline Forms Thereof | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2014-09-11 | — | — | US | disclosed |
| US-8722722-B2 | Raltegravir salts and crystalline forms thereof | TEVA PHARMACEUTICAL INDUSTRIES LTD (US) | 2014-05-13 | — | — | US | disclosed |
| US-20130096147-A1 | Raltegravir Salts and Crystalline Forms Thereof | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2013-04-18 | — | — | US | disclosed |
| US-20130079360-A1 | RALTEGRAVIR SALTS AND CRYSTALLINE FORMS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2013-03-28 | — | — | US | disclosed |
| EP-2545048-A1 | RALTEGRAVIR SALTS AND CRYSTALLINE FORMS THEREOF | Teva Pharmaceutical Industries Ltd. (IL) | 2013-01-16 | — | — | EP | disclosed |
| WO-2011123754-A1 | RALTEGRAVIR SALTS AND CRYSTALLINE FORMS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256755-A1 | Raltegravir Salts And Crystalline Forms Thereof | SAMHD1, KLK5, KLK4 | KCNE1 651/4885CCR1 1137/4885KCNQ1 208/4885 |
| US-20130096147-A1 | Raltegravir Salts and Crystalline Forms Thereof | SAMHD1, KLK5, KLK4 | KCNE1 651/4885CCR1 1137/4885KCNQ1 208/4885 |
| US-20130079360-A1 | RALTEGRAVIR SALTS AND CRYSTALLINE FORMS THEREOF | SAMHD1, KLK5, KLK4 | KCNE1 651/4885CCR1 1137/4885KCNQ1 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.